Oncology

Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&D and reaching the extracellular targets. Although priority will be on testing a combination of pozelimab, Regeneron's C5 antibody in Phase 1 trial and cemdisiran, Alnylam's RNAi anti-C5 therapy, now in Phase 2. Drugs to Train Immune cells to Target Cancer Researchers at Mount Sinai School of Medicine in New York, have positive outcomes that FDA app...